Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amyris Inc    AMRS

AMYRIS INC (AMRS)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

AMYRIS : Amyris's First Commercial Production Facility Complete and Operational

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/29/2011 | 02:05pm CEST

Amyris, Inc., (NASDAQ:AMRS), a renewable chemicals and fuels company, today announced the completion of the first industrial-scale facility for the production of Biofene?, Amyris's renewable farnesene. The production facility is located in Piracicaba, São Paulo, Brazil at a facility owned by Biomin do Brasil Nutri?ão Animal Ltda., a company focusing on animal nutrition. Amyris will operate the production facility and expects to begin Biofene production in May. To produce Biofene, Amyris feeds sugar cane syrup into three dedicated 200,000 liter fermentors containing Amyris proprietary yeast. The yeast digest the syrup feedstock and produce farnesene, which is then separated and purified. Biofene may then be sold directly into industrial applications or put through simple chemical finishing steps to form a broad range of renewable products including squalane, base oil and finished lubricants and diesel.

To achieve production at full industrial scale, Amyris has developed an integrated scale-up process which connects ongoing advances in Amyris research with industrial-scale production. By miniaturizing process conditions found in production-scale fermentors, Amyris has been able to translate yeast performance successfully from discovery to production. Amyris further controls scale-up by testing performance in its pilot plant in Emeryville, Calif., followed by vetting in a second pilot plant and a demonstration facility in Amyris's operations in Campinas, Brazil. Earlier this year, Amyris tested its yeast strains and process in several runs at 100,000 and 200,000 liter scale and generated results that were consistent with previous runs at smaller scale.

"The completion of our first Biofene production facility is a landmark not only for Amyris but also for the renewable products sector," said John Melo, CEO of Amyris. "With this milestone, we are demonstrating that engineered yeast may be used to produce high-value hydrocarbon molecules on a commercial scale. This achievement reinforces our goal of providing No Compromise® renewable alternatives to petroleum to transform the chemicals industry, extend the world's fuel supply and contribute to the betterment of our environment."

Amyris is scaling its production through contract agreements with manufacturers located in Brazil, Europe and the United States, and has five production agreements in place including contract agreements with Antibioticós S.A., Biomin, Paraíso Bioenergia S.A., Tate & Lyle Ingredients Americas, Inc., an affiliate of Tate & Lyle PLC, and a joint venture with Usina São Martinho S.A., one of the largest sugar and ethanol producers in Brazil. Amyris has also established finishing capabilities with Glycotech, Inc.

About Amyris, Inc.

Amyris is an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris uses its industrial synthetic biology platform to convert plant sugars into a variety of hydrocarbon molecules - flexible building blocks which can be used in a wide range of products. Amyris is commercializing these products both as No Compromise® renewable ingredients in cosmetics, flavors and fragrances, polymers, lubricants and consumer products, and also as No Compromise renewable diesel and jet fuel. Amyris Brasil S.A., a wholly owned subsidiary, has over 100 employees based in Campinas, Brazil and oversees Amyris's production and commercialization in Brazil. Amyris also has fuel distribution capabilities in the United States through its subsidiary, Amyris Fuels LLC. More information about Amyris is available at www.amyris.com.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as statements regarding commercial-scale production and commercialization and anticipated benefits of our products) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in development, production or commercialization of products, our reliance on third parties to achieve our goals, and other risks detailed in the "Risk Factors" section of Amyris's annual report on Form 10-K filed on March 14, 2011. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris, Biofene and No Compromise are trademarks or registered trademarks of Amyris, Inc.

Schwartz Communications
Merrill Freund or Alison Mickey, 415-817-2557
[email protected]


© Business Wire 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMYRIS INC
04/26AMYRIS : Biossance – World Malaria Day
PU
04/18AMYRIS, INC. : Regulation FD Disclosure (form 8-K)
AQ
04/17AMYRIS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
04/12AMYRIS, INC. (NASDAQ : AMRS) Files An 8-K Entry into a Material Definitive Agree..
AQ
04/12AMYRIS, INC. : Entry into a Material Definitive Agreement, Financial Statements ..
AQ
04/11AMYRIS : Biossance – Introducing 3 New Ways to Sample
PU
04/06AMYRIS, INC. (NASDAQ : AMRS) Files An 8-K Entry into a Material Definitive Agree..
AQ
04/06AMYRIS : to Present at H.C. Wainwright Global Life Sciences Investment Conferenc..
AQ
04/05AMYRIS, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
04/04AMYRIS : to Present at H.C. Wainwright Global Life Sciences Investment Conferenc..
AQ
More news
News from SeekingAlpha
2017Amyris (AMRS) Investor Presentation - Slideshow 
2017Amyris' (AMRS) CEO John Melo on Q1 2017 Results - Earnings Call Transcript 
2017Amyris misses by $0.04, misses on revenue 
2017Notable earnings after Monday?s close 
2017INSIDERINSIGHTS.COM DAILY ROUND UP 4 : Apollo Global, Pulse Biosciences, Acacia .. 
Financials ($)
Sales 2018 189 M
EBIT 2018 -6,33 M
Net income 2018 -28,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019 31,86
Capi. / Sales 2018 1,51x
Capi. / Sales 2019 1,02x
Capitalization 284 M
Chart AMYRIS INC
Duration : Period :
Amyris Inc Technical Analysis Chart | AMRS | US03236M1018 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 12,5 $
Spread / Average Target 87%
EPS Revisions
Managers
NameTitle
John G. Melo President, Chief Executive Officer & Director
Geoffrey M. Duyk Chairman
Eduardo Alvarez Chief Operating Officer
Kathleen Valiasek Chief Financial Officer
Joel Cherry President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
AMYRIS INC-67.12%284
HENKEL-6.93%52 431
ECOLAB8.19%42 171
SIKA-7.24%16 058
SYMRISE-8.01%10 631
INDORAMA VENTURES PCL--.--%10 368